The Place of Probiotics in Human Intestinal Infections | CMAC

The Place of Probiotics in Human Intestinal Infections

Clinical Microbiology and Antimicrobial Chemotherapy. 2003; 5(3):275-284

​ Sullivan A., Nord C.E.
probiotics intestinal infections diarrhoea
Section
Antimicrobials
Type
Journal article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2003; 5(3):275-284

Abstract

Reprinted from «International Journal of Antimicrobial Agents» 2002; 20:313,9 – with permission from Elsevier. (The translation has not been rewieved by Elsevier prior to printing).

A number of studies have been carried out on the effect of several probiotic species on treatment and prevention of intestinal infections. The most commonly used microorganisms are lactic,acid producing bacteria such as lactobacilli and bifidobacteria belonging to the human normal microflora. In vitro and animal studies have shown that probiotic microorganisms interfere with the colonization of Helicobacter pylori and of enteropathogenic micro-organisms. In humans the significance is more uncertain. Clinically significant benefits of probiotics have been demonstrated in the treatment of rotavirus induced diarrhoea and of Saccharomyces boulardii in the prevention of antibiotic,associated diarrhoea. In patient suffering from inflammatory bowel disease, several probiotic strains have been shown to be as effective as traditional medication in preventing relapses. Standardised and well performed studies are needed to elucidate further the mechanisms of action and the clinical significance of probiotics.

  • 1. Fuller R. Probiotics in man and animals. J Appl Bacteriol 1989;66:365-78.
  • 2. Havenaar R., Huis in’t Veld J.H.J. Probiotics: a general view. In: Wood B.J.B., editor. The lactic acid bacteria in health and disease. Amsterdam: Elsevier; 1992.р.1-200.
  • 3. Metchnikoff E. The prolongation of life. New York: GP Putnam’s Sons; 1907.
  • 4. Michetti P., Dorta G., Wiesel P.H., et al. Effect of wheybased culture supernatant of Lactobacillus acidophilus (johnsonii) La1 on Helicobacter pylori infection in humans. Digestion 1999;60:203-9.
  • 5. Silva M., Jacobus N.V., Deneke C., Gorbach S.L. Antimicrobial substance from a human Lactobacillus strain. Antimicrob Agents Chemother 1987;31:1231-3.
  • 6. Forestier C., De Champs C., Vatoux C., Joly B. Probiotic activities of Lactobacillus casei rhamnosus: in vitro adherence to intestinal cells and antimicrobial properties. Res Microbiol 2001;152:167-73.
  • 7. Sanders M.E. Considerations for use of probiotic bacteria to modulate human health. J Nutr 2000;130:384S-90S.
  • 8. Franz C.M., Holzapfel W.H., Slites M.E. Enterococci at the crossroads of food safety. Int J Food Microbiol 1999;47:1-24.
  • 9. Lund B., Edlund C. Probiotic Enterococcus faecium strain is a possible recipient of the vanA gene cluster. Clin Infect Dis 2001;32:1384-5.
  • 10. Davidson J.N., Hirsch D.C. Bacterial competition as a means of preventing diarrhoea in pigs. Infect Immunol 1976;13:1773-4.
  • 11. Hoa N.T., Baccigalupi L., Huxham A., et al. Characterization of Bacillus species used for oral bacteriotherapy and bacterioprophylaxis of gastrointestinal disorders. Appl Environ Microbiol 2000;66:5241-7.
  • 12. Castagliuolo I., Qiu B.S., Lamont J.T., Pothoulakis C. Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum. Infect Immun 1996;64:5225-32.
  • 13. Malfertheiner P., Megraud F., O’Morain C., et al. Current concepts in the management of Helicobacter pylori infection – the Maastricht 2 – consensus report. Aliment Pharmacol Ther 2000;16:167-80.
  • 14. Adamsson I., Edlund C., Nord C.E. Microbial ecology and treatment of Helicobacter pylori infections: review. J Chemother 2000;12:5-16.
  • 15. Cremonini F., Canducci F., Di Caro S., et al. Helicobacter pylori treatment: a role for probiotics. Digest Dis 2001;19:144-7.
  • 16. Midolo P.D., Lambert J.R., Hull R., Luo F., Grayson M.L. In vitro inhibition of Helicobacter pylori NCTC 11637 by organic acids and lactic acid bacteria. J Appl Bacteriol 1995;79:475-9.
  • 17. Mukai T., Asasaka T., Sato E., Mori K., Matsumoto M., Ohori H. Inhibition of binding of Helicobacter pylori to the glycolipid receptors by probiotic Lactobacillus reuteri. FEMS Immunol Med Microbiol 2002;32:105-10.
  • 18. Pinchuk I.V., Bressollier P., Verneuil B., et al. In vitro anti-Helicobacter pylori activity of the probiotic strain Bacillus subtilis 3 is due to secretion of antibiotics. Antimicrob Agents Chemother 2001;45:3156-61.
  • 19. Kabir A.M., Aiba Y., Takagi A., Kamiya S., Miwa T., Koga Y. Prevention of Helicobacter pylori infection by lactobacilli in a gnotobiotic murine model. Gut 1997;41:49-55.
  • 20. Sakamoto I., Igarashi M., Kimura K., Takagi A., Miwa T., Koga Y. Suppressive effect of Lactobacillus gasseri OLL 2716 (LG21) on Helicobacter pylori infection in humans. J Antimicrob Chemother 2001;47:709-10.
  • 21. Adachi J.A., Ostrosky-Zeichner L., DuPont H.L., Ericsson C.D. Empirical antimicrobial therapy for traveller’s diarrhoea. Clin Infect Dis 2000;31:1079-83.
  • 22. Sanders J.W., Tribble D.R. Diarrhoea in the returned traveler. Curr Gastroenterol Rep 2001;3;304-14.
  • 23. Tuomola E.M., Owehand A.C., Salminen S.J. The effect of probiotic bacteria on adhesion of pathogens to human intestinal mucus. FEMS Immunol Med Microbiol 1999;26:137-42.
  • 24. Lehto E.M., Salminen S.J. Inhibition of Salmonella typhimurium adhesion to Caco-2 cell cultures by Lactobacillus strain GG spent culture supernate: only a pH effect. FEMS Immunol Med Microbiol 1997;18:125-32.
  • 25. Asahara T., Nomoto K., Shimizu K., Watanuki M., Tanaka R. Increased resistance of mice to Salmonella enterica serovar Typhimurium infection by symbiotic administration of bifidobacteria and transgalactosylated oligosaccharides. J Appl Microbiol 2001;91:985-96.
  • 26. Madsen K., Cornish A., Soper P., et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 2001;121:580-91.
  • 27. Lewis S.J., Freedman A.R. Review article: the use of biotherapeutic agents in the prevention and treatment of gastrointestinal disease. Aliment Pharmacol Ther 1998;12:807-22.
  • 28. Black F.T., Anderson P.L., Orskov J., Gaarslev K., Laulund S. Prophylactic efficacy of lactobacilli on traveller’s diarrhoea. Travel Med 1989;7:333-5.
  • 29. Guandalini S., Pensabene L., Zikri M., et al. Lactobacillus GG administered in oral rehydration solution to children with acute diarrhoea: a multicenter European trial. J Pediatr Gastroenterol Nutr 2000;30:54-60.
  • 30. Marteau P.R., de Vrese M., Cellier C.J., Schrezenmeir J. Protection from gastrointestinal diseases with the use of probiotics. Am J Clin Nutr 2001;7 (Suppl):430S-6S.
  • 31. Ciarlet M., Estes M.K. Interactions between rotavirus and gastrointestinal cells. Curr Opin Microbiol 2001;4:435-41.
  • 32. Isolauri E., Kaila M., Mykkanen H., Ling W.H., Salminen S. Oral bacteriotherapy for viral gastroenteritis. Digest Dis Sci 1994;39:2595-600.
  • 33. Kaila M., Isolauri E., Soppi E., Virtanen E., Laine S., Arvilommi H. Enhancement of the circulating antibody secreting cell response in human diarrhoea by a human Lactobacillus strain. Pediatr Res 1992;32:141-4.
  • 34. Szajewska H., Mrukowicz J.Z. Probiotics in the treatment and prevention of acute infectious diarrhoea in infants and children: a systematic review of published randomized, double-blind, placebo-controlled trials. J Pediatr Gastroenterol Nutr 2001;33(Suppl 2):S17-25.
  • 35. Van Niel C.W., Feudtner C., Garrison M.M., Christakis D.A. Lactobacillus therapy for acute infectious diarrhoea in children: a meta-analysis. Pediatrics 2002;109:678-84.
  • 36. Shu Q., Qu F., Gill H.S. Probiotic treatment using Bifidobacterium lactis HN019 reduces weanling diarrhoea associated with rotavirus and Escherichia coli infection in a piglet model. J Pediatri Gastroenterol Nutr 2001;3:171-7.
  • 37. Saavedra J.M., Bauman N.A., Oung I., Perman J.A., Yolken R.H. Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhoea and shedding of rotavirus. Lancet 1994;344:1046-9.
  • 38. Szajewska H., Kotowska M., Mrukowicz J.Z., Armanska M., Mikotajczyk W. Efficacy of Lactobacillus GG in prevention of nosocomial diarrhoea in infants. J Pediatr 2001;138:361-5.
  • 39. Oberhelman R.A., Gilman R.H., Sheen P., et al. A placebo-controlled trial of Lactobacillus GG to prevent diarrhoea in undernourished Peruvian children. J Pediatr 1999;134:15-20.
  • 40. Bergogne-Berezin E. Treatment and prevention of antibiotic associated diarrhoea. Int J Antimicrob Agents 2000;16:521-6.
  • 41. Barbut F., Petit J.C. Epidemiology of Clostridium difficile-associated infections. Clin Microbiol Infect 2001;7:405-10.
  • 42. Barbut F., Richard A., Hamadi K., Chomette V., Burghoffer B., Petit J.C. Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhoea. J Clin Microbiol 2000;38:2386-8.
  • 43. Kyne L., Kelly C.P. Recurrent Clostridium difficile diarrhoea. Gut 2001;49:152-3.
  • 44. Arvola T., Laiho K., Torkkeli S., et al. Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhoea in children with respiratory infections: a randomized study. Pediatrics 1999;104:e64.
  • 45. Vanderhoof J.A., Whitney D.B., Antonsson D.L., et al. Lactobacillus GG in the prevention of antibiotic-associated diarrhoea in children. J Pediatr 1999;135:564-8.
  • 46. Thomas R.M., Litin S.C., Osmon D.R., et al. Lack of effect of Lactobacillus GG on antibiotic-associated diarrhoea: a randomised, placebo-controlled trial. Mayo Clin Proc 2001;76:883-9.
  • 47. Castagliuolo I., Riegler M.F., Valenick L., Lamont J.T., Pothoulakis C. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect Immun 1999;67:302-7.
  • 48. McFarland L.V., Surawicz C.M., Greenberg R.N., et al. A randomised placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. J Am Med Assoc 1994; 271:1913-8.
  • 49. Surawicz C.M., McFarland L.V. Greenberg R.N., et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 2000;31:1012-7.
  • 50. Linskens R.K., Huijsdens X.W., Savelkoul P.H.M., Vandenbroucke-Grauls C.M.J.E., Meuwissen S.G.M. The bacterial flora in inflammatory bowel disease: current insights in pathogenesis and the influence of antibiotics and probiotics. Scand J Gastroenterol 2001;36(Suppl. 234):29-40.
  • 51. Shanahan F. Crohn’s disease. Lancet 2002;359:62-9.
  • 52. Shanahan F. Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics. Gastroenterology 2001;120:622-35.
  • 53. Mutlu E.A., Farhadi A., Keshavarzian A. New developments in the treatment of inflammatory bowel disease. Expert Opin Invest Drugs 2002;11:365-85.
  • 54. Madsen K.L., Doyle J.S., Jewell L.D., Tavernini M.M., Fedorak R.N. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology 1999;116:1107-14.
  • 55. Steidler L., Hans W., Schotte L., et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin10. Science 2000;289:1352-5.
  • 56. Malin M., Suomalainen H., Saxelin M., Isolauri E. Promotion of IgA immune response in patients with Crohn’s disease by oral bacteriotherapy with Lactobacillus GG. Ann Nutr Metab 1996;40:137-45.
  • 57. Rembecken B.J., Snelling A.M., Hawkey P.M., Chalmers D.M., Axon A.T.R. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999;354:635-9.
  • 58. Kruis W., Schutz E., Fric P., Fixa B., Judmaiier G., Stolte M. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997;11: 853-8.
  • 59. Malchow H.A. Crohn’s disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn’s disease. J Clin Gastroenterol 1997;25:653-8.
  • 60. Venturi A., Gionchetti P., Rizzello F., et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 1999;13:1103-8.
  • 61. Gionchetti P., Rizzello F., Venturi A., et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000;119:305-9.
  • 62. Campieri M., Rizzello F., Venturi A., et al. Combination of antibiotic and probiolic treatment is efficacious in prophylaxis of post-operative recurrence of Crohn’s disease: a randomised controlled study vs. mesalamine. Gastroenterology 2000;118:A4178.
  • 63. Guslandi M., Mezzi G., Sorghi M., Testoni P.A. Saccharomyces boulardii in maintenance treatment of Crohn’s disease. Digest Dis Sci 2000;45:1462-4.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared